Luko Čekanavičiaus laboratorija, MB - financials and debts
Company age: 7 y. 10 mo.
Luko Čekanavičiaus laboratorija - Company finances
|
EUR
|
2018
From: 2018-11-08
To: 2018-12-31
|
2019
From: 2019-01-01
To: 2019-12-31
|
2020
From: 2020-01-01
To: 2020-12-31
|
2021
From: 2021-01-01
To: 2021-12-31
|
2022
From: 2022-01-01
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|---|---|---|---|
|
Financial data
|
||||||||
| Sales revenue | - | 12,974 | 42,342 | 91,553 | 101,770 | 95,058 | 96,197 | 100,634 |
| Profit before tax | -430 | 2,144 | 22,546 | 22,182 | 5,081 | -5,200 | -5,493 | 46 |
| Net profit | -430 | 2,034 | 21,398 | 21,068 | 4,825 | -5,142 | -5,493 | 45 |
| Equity | -330 | 1,704 | 23,103 | 29,905 | 24,689 | 19,404 | 13,911 | 13,956 |
| Liabilities | - | - | - | - | 5,432 | 4,401 | 8,396 | 11,496 |
| Non-current assets | 0 | 642 | 6,271 | 9,105 | 17,555 | 18,072 | 14,144 | 8,431 |
| Current assets | 70 | 2,703 | 18,239 | 25,495 | 12,566 | 5,733 | 8,163 | 17,021 |
| Total assets | 70 | 3,345 | 24,510 | 34,600 | 30,121 | 23,805 | 22,307 | 25,452 |
|
Taxes paid
|
||||||||
| STI taxes | - | - | - | - | - | 261 | - | - |
|
Financial indicators
|
||||||||
| Revenue change y/y | - | - | +226.4% | +116.2% | +11.2% | -6.6% | +1.2% | +4.6% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | -614.3% | 60.8% | 87.3% | 60.9% | 16.0% | -21.6% | -24.6% | 0.2% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | - | 119.4% | 92.6% | 70.4% | 19.5% | -26.5% | -39.5% | 0.3% |
| Profit margin Net profit margin. Shows the overall profitability of the company. | - | 15.7% | 50.5% | 23.0% | 4.7% | -5.4% | -5.7% | 0.0% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | - | 16.5% | 53.2% | 24.2% | 5.0% | -5.5% | -5.7% | 0.0% |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | - | - | - | - | 0.2 | 0.2 | 0.6 | 0.8 |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | - | - | - | - | - | - | - | - |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
Luko Čekanavičiaus laboratorija - Social security debts
The amount of overdue SODRA debt for the company Luko Čekanavičiaus laboratorija as of the last working day is: 161 €
| From | To | Debt, € |
|---|---|---|
| 2026-09-05 | 2026-09-14 | 160.96 |
| 2026-09-01 | 2026-09-02 | 160.96 |
| 2026-08-26 | 2026-08-31 | 80.48 |
| 2026-08-23 | 2026-08-23 | 80.48 |
| 2026-08-19 | 2026-08-19 | 80.48 |
| 2026-08-16 | 2026-08-17 | 80.48 |
| 2026-08-01 | 2026-08-14 | 80.48 |
| 2026-07-01 | 2026-07-31 | 241.44 |
| 2026-06-02 | 2026-06-30 | 160.96 |
| 2026-05-03 | 2026-06-01 | 80.48 |
| 2026-04-01 | 2026-04-30 | 241.44 |
| 2026-03-03 | 2026-03-31 | 160.96 |
| 2026-02-03 | 2026-03-02 | 80.48 |
| 2026-01-01 | 2026-01-31 | 289.80 |
| 2025-12-02 | 2025-12-31 | 217.35 |
| 2025-11-01 | 2025-12-01 | 144.90 |
| 2025-10-01 | 2025-10-31 | 72.45 |
| 2025-09-02 | 2025-09-30 | 144.90 |
| 2025-08-01 | 2025-09-01 | 72.45 |
| 2025-07-01 | 2025-07-31 | 289.80 |
| 2025-06-03 | 2025-06-30 | 217.35 |
| 2025-05-04 | 2025-06-02 | 144.90 |
| 2025-04-01 | 2025-04-30 | 72.45 |
| 2025-03-04 | 2025-03-31 | 144.90 |
| 2025-03-03 | 2025-03-03 | 72.45 |
| 2025-03-01 | 2025-03-02 | 144.90 |
| 2025-02-01 | 2025-02-28 | 72.45 |
| 2025-01-02 | 2025-01-31 | 258.00 |
| 2024-12-03 | 2024-12-31 | 193.50 |
| 2024-11-04 | 2024-12-02 | 129.00 |
| 2024-10-01 | 2024-11-03 | 64.50 |
| 2024-09-03 | 2024-09-30 | 129.00 |
| 2024-08-01 | 2024-09-02 | 64.50 |
| 2024-07-02 | 2024-07-31 | 258.00 |
| 2024-06-03 | 2024-07-01 | 193.50 |
| 2024-05-02 | 2024-06-02 | 129.00 |
| 2024-04-03 | 2024-05-01 | 64.50 |
| 2024-03-22 | 2024-03-31 | 52.51 |
| 2024-03-01 | 2024-03-21 | 363.52 |
| 2024-02-01 | 2024-02-29 | 299.02 |
| 2024-01-03 | 2024-01-31 | 234.52 |
| 2023-12-01 | 2024-01-02 | 175.89 |
| 2023-11-03 | 2023-11-30 | 117.26 |
| 2023-10-03 | 2023-11-02 | 58.63 |
| 2023-09-01 | 2023-09-30 | 117.26 |
| 2023-08-01 | 2023-08-31 | 58.63 |
| 2023-07-03 | 2023-07-31 | 234.52 |
| 2023-06-01 | 2023-07-02 | 175.89 |
| 2023-05-04 | 2023-05-31 | 117.26 |
| 2023-05-02 | 2023-05-03 | 58.63 |
| 2023-04-03 | 2023-04-30 | 58.63 |
| 2023-03-01 | 2023-03-31 | 58.63 |
| 2023-02-01 | 2023-02-28 | 109.58 |
| 2023-01-03 | 2023-01-31 | 50.95 |
| 2022-12-01 | 2022-12-31 | 152.85 |
| 2022-11-03 | 2022-11-30 | 101.90 |
| 2022-10-03 | 2022-11-02 | 50.95 |
| 2022-09-01 | 2022-09-30 | 203.80 |
| 2022-08-02 | 2022-08-31 | 152.85 |
| 2022-07-01 | 2022-08-01 | 101.90 |
| 2022-05-03 | 2022-06-30 | 50.95 |
Luko Čekanavičiaus laboratorija - VMI tax arrears
The company had no tax arrears (debts) to the State Tax Inspectorate
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
Luko Cekanaviciaus laboratorija, MB (code 304947697) is a small partnership engaged in the manufacture of other medical and dental devices, instruments and supplies. In 2025, the company generated revenue of €100.6K and recorded net profit of €45, after net losses of €5.1K in 2023 and €5.5K in 2024. This shows a gradual improvement in operating performance, although profitability remained very thin in the latest year, with a near-breakeven margin. Revenue rose from €95.1K in 2023 to €96.2K in 2024 and then to €100.6K in 2025, reflecting moderate growth over the period. The balance sheet also expanded modestly, with total assets increasing to €25.5K in 2025 from €23.8K in 2023. Equity stood at €14.0K and liabilities at €11.5K in 2025, resulting in an equity ratio of 54.8% and a debt-to-equity ratio of 0.82. Asset turnover reached 3.95x, while ROE was 0.3% and ROA 0.2% in 2025.